← Back to Search

Individualized Interventions for Breast Cancer (MyCHOICE Trial)

N/A

Waitlist Available

Led By Shahid Ahmed, MD, PhD

Research Sponsored by University of Saskatchewan

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Premenopausal women with histologically-proven, completely resected, hormone receptor-positive (defined as ER≥10% and/or PgR≥10%) stage 1, 2, and 3 invasive breast cancer who are treated with combination of anti-estrogen therapy (LHRH agonist and an aromatase inhibitor or tamoxifen)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to three years from the time of enrolment

Awards & highlights

MyCHOICE Trial Summary

This trial will test if interventions can help improve quality of life for women with early stage hormone receptor positive breast cancer.

Who is the study for?

This trial is for premenopausal women with early-stage breast cancer that's hormone receptor-positive and has been surgically removed. Participants must be on a combination of anti-estrogen therapies. Post-menopausal women or those on single agent endocrine therapy cannot join.Check my eligibility

What is being tested?

The study tests if tailored behavioral and complementary interventions can improve quality of life and adherence to treatment in young women undergoing combined endocrine therapy for breast cancer, by monitoring changes in their quality of life and treatment adherence.See study design

What are the potential side effects?

While the trial itself focuses on improving tolerance, common side effects from the underlying endocrine treatments may include hot flashes, mood swings, fatigue, bone density loss, joint pain, and sexual dysfunction.

MyCHOICE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am a premenopausal woman with a certain type of early-stage breast cancer that has been fully removed and am on specific hormone therapy.

MyCHOICE Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to three years from the time of enrolment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to three years from the time of enrolment

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to three years from the time of enrolment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Functional Assessment of Cancer Therapy - Breast Symptom Index (FACT-B)

Secondary outcome measures

Functional Assessment of Cancer Therapy - (FACT)-Cognitive

Functional Assessment of Cancer Therapy - Endocrine System (FACT-ES)

Treatment discontinuation rate

MyCHOICE Trial Design

1Treatment groups

Experimental Treatment

Group I: Individualized interventionsExperimental Treatment1 Intervention

Exercise, Yoga, massage therapy, acupuncture, and others

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of SaskatchewanLead Sponsor

251 Previous Clinical Trials

154,369 Total Patients Enrolled

1 Trials studying Breast Cancer

450 Patients Enrolled for Breast Cancer

Shahid Ahmed, MD, PhDPrincipal InvestigatorUniversity of Saskatchewan

2 Previous Clinical Trials

59 Total Patients Enrolled

Media Library

Individualized interventions Clinical Trial Eligibility Overview. Trial Name: NCT03407768 — N/A

Breast Cancer Research Study Groups: Individualized interventions

Breast Cancer Clinical Trial 2023: Individualized interventions Highlights & Side Effects. Trial Name: NCT03407768 — N/A

Individualized interventions 2023 Treatment Timeline for Medical Study. Trial Name: NCT03407768 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research currently recruiting participants?

"According to clinicaltrials.gov, this medical trial is not currently accepting new candidates; the original posting was on July 1st 2018 and it has most recently been modified on May 16th 2022. Despite this study's inactive status, a plethora of alternative trials are presently recruiting patients."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Role of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast Cancer

Shahid Ahmed 2018. "Role of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03407768.

All > Acth